Repatha (Evolocumab)

Evolocumab is a medicine used to lower "bad" LDL cholesterol and the risk of heart attack and stroke. It works by helping the liver pull more cholesterol out of the blood. It's given as a shot under the skin.

Brand names:Repatha
Medication

What people taking Repatha (Evolocumab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Repatha (Evolocumab) for High Cholesterol (Hypercholesterolemia)?

NameHow it went

About Repatha (Evolocumab)

What It's For

Evolocumab, sold under the brand name Repatha, is an injectable prescription medicine that lowers LDL (low-density lipoprotein) cholesterol, often called "bad" cholesterol because it builds up in artery walls and narrows them. Its main use is to reduce the risk of heart attack, stroke, death from heart disease and the need for procedures to reopen blocked arteries in adults at increased risk of these events. That includes people who have already had a heart attack or stroke, and also higher-risk adults who have not, such as people with narrowed arteries or long-standing diabetes. Along with diet and exercise, it is also approved to lower LDL cholesterol in adults with high cholesterol, and in adults and children aged 10 and older with familial hypercholesterolemia, a form of high cholesterol that runs in families. There are two versions of that condition: heterozygous, the more usual type, and homozygous, a rare and much more severe type. Evolocumab belongs to a group of medicines called PCSK9 inhibitors. In its major heart trials it was added to a statin or other cholesterol-lowering treatment people were already taking, rather than replacing it.

How It Works

The liver is the main place LDL cholesterol is removed from the blood. Its cells capture LDL using docking sites on their surface called LDL receptors. A protein called PCSK9 attaches to these receptors and causes them to be broken down, so the liver ends up with fewer of them and more LDL stays in circulation. Evolocumab is a monoclonal antibody, a lab-made protein designed to attach to one specific target, and its target is PCSK9. With PCSK9 blocked, more LDL receptors remain available and the liver clears more LDL from the blood. In a large trial of people already taking a statin, adding evolocumab lowered LDL by about 59% compared with placebo. Less LDL in the blood means less cholesterol available to build up in artery walls, which is how lower LDL translates into fewer heart attacks and strokes over time.

Dosage & Administration

Evolocumab is injected under the skin of the belly, thigh or upper arm, using a single-dose prefilled pen, autoinjector or syringe. Most people use either one 140 mg injection every 2 weeks or a 420 mg dose once a month. The monthly dose is given as three injections, one after another, within 30 minutes. People with the homozygous form of familial hypercholesterolemia usually start with the monthly dose, which the prescriber may increase to every 2 weeks if LDL has not fallen enough after 12 weeks. The care team shows people how to inject, and each injection takes up to about 15 seconds. The medicine is kept in the refrigerator in its carton, then left out for at least 30 minutes to reach room temperature before injecting. If needed, it can be kept at room temperature in the carton for up to 30 days, after which it should be thrown away. Do not freeze or shake it, and do not use it if the liquid looks cloudy, discolored or has particles in it. Rotate injection sites and avoid skin that is tender, bruised, red, hard or scarred. If a dose is missed and no more than 7 days have passed, inject it and continue the original schedule. If more than 7 days have passed, someone on the every-2-week schedule waits for the next planned dose, while someone on the monthly schedule injects now and starts a new monthly schedule from that date.

Side Effects

The most common side effects in trials were cold-like symptoms such as a runny nose or sore throat, flu or flu-like symptoms, back pain, and redness, pain or bruising where the injection was given. These occurred only slightly more often than with placebo injections, and few people stopped treatment because of side effects. In the largest heart trial, new diabetes was diagnosed in slightly more people taking evolocumab than placebo (8.1% versus 7.7% of those who did not have diabetes at the start), so the label lists high blood sugar among its common effects. Serious allergic reactions are uncommon but have been reported, including angioedema, a deeper swelling under the skin. Stop using evolocumab and call 911 for trouble breathing or swallowing, or swelling of the face, lips, tongue or throat. For hives, rash or itching without those signs, stop the injections and call the prescriber right away.

Interactions & Warnings

Evolocumab should not be used by anyone who has had a serious allergic reaction to it or to any of its ingredients. Some autoinjectors and prefilled syringes have a needle cover made with natural rubber latex, which can cause a reaction in people sensitive to latex. The carton says whether a product contains it, and latex-free versions, including the prefilled pen, are available, so tell the prescriber about a latex allergy before the first prescription is filled. The prescribing information does not list specific drug interactions for evolocumab. It is still worth giving the prescriber and pharmacist a full list of medicines and supplements, especially other cholesterol treatments, so the overall plan stays coordinated. There is too little information to know whether evolocumab is safe during pregnancy. Like other antibody medicines, it can cross the placenta to the developing baby, particularly later in pregnancy, so anyone pregnant or planning a pregnancy should discuss whether to continue. It is not known whether evolocumab passes into breast milk. In children, it has been studied only for familial hypercholesterolemia from age 10.

What to Expect

Evolocumab lowers cholesterol quickly: LDL reaches its lowest point within 2 to 3 weeks of a dose, and a blood test as early as 4 weeks after starting can show how well it is working. LDL is reported in milligrams per deciliter (mg/dL), and lower is better for people at risk of heart disease. In the large trial of people with heart disease, the median LDL fell from 92 to 30 mg/dL. People on the monthly dose may be asked to have their test just before the next injection, because in some people levels vary over the course of the month. Studies following people for several years found no link between these very low LDL levels and problems with memory or thinking. The cholesterol change cannot be felt, and the protection against heart attacks and strokes builds over years. In people with established heart or blood vessel disease, about two years of treatment lowered the share who had a heart attack, stroke or heart-related death from 7.4% to 5.9%. In higher-risk people who had never had a heart attack or stroke, the estimated five-year rate of a first heart attack, stroke or death from heart disease fell from 8.0% to 6.2%. The benefit lasts only as long as treatment continues: if evolocumab is stopped, cholesterol levels rise again, so it is usually a long-term medicine. People with the homozygous form of familial hypercholesterolemia tend to see smaller and more variable reductions, and some with the most severe genetic changes do not respond.

Questions to Ask Your Doctor

  1. 1.What LDL level are we aiming for, and how will we know evolocumab is getting me there?
  2. 2.Should I continue my statin or other cholesterol medicines alongside evolocumab?
  3. 3.Is the every-2-week or the monthly schedule a better fit for me, and which device should I use?
  4. 4.Will my insurance cover evolocumab, and what happens if coverage changes?
  5. 5.How should we handle evolocumab if I am planning a pregnancy?

Last reviewed • Oct 2026

Educational content, not medical advice.